FTC, Catalent and Novo Holdings
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. | A dozen consumer groups and trade unions penned a letter to Lina Khan,
We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.
Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...
Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...
Novo Nordisk announced the European Medicines Agency's CHMP has adopted a positive opinion, recommending approval of Alhemo as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback